Snapshot from Apr 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Inovio Pharmaceuticals Faces...
Regulatory securities lawsuit

Inovio Pharmaceuticals Faces Securities Class Action

Analysis based on 89 articles · First reported Feb 09, 2026 · Last updated Mar 30, 2026

Sentiment
-30
Attention
2
Articles
89
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of a securities class action against Inovio Pharmaceuticals, leading to a significant drop in Inovio Pharmaceuticals' stock price. This event highlights regulatory scrutiny in the pharmaceutical sector, potentially increasing investor caution.

Pharmaceuticals Legal Services
Event Summary

Faruqi & Faruqi, a national securities law firm, is investigating Inovio Pharmaceuticals for potential federal securities law violations. The firm is reminding investors of the April 7, 2026 deadline to seek lead plaintiff status in a class action lawsuit. The complaint alleges that Inovio Pharmaceuticals made false and misleading statements regarding deficiencies in manufacturing its CELLECTRA device, the likelihood of submitting the INO-3107 BLA to the United States===Food and Drug Administration by the second half of 2024, and insufficient information to justify accelerated approval or priority review for INO-3107. This follows the United States===Food and Drug Administration's December 29, 2025 announcement that it accepted Inovio Pharmaceuticals' BLA for INO-3107 on a standard review timeline, stating the company did not provide adequate information for accelerated approval. Inovio Pharmaceuticals' stock price fell 24.45% on this news.

Key Actions
95 United States===Food and Drug Administration accepted Biologics License Application on standard review timeline Inovio Pharmaceuticals
90 Faruqi & Faruqi investigating potential claims and encouraging investors to join class action Inovio Pharmaceuticals
90 Inovio Pharmaceuticals stock price fell due to FDA decision
90 Faruqi & Faruqi investigating potential claims and encouraging investors to join a class action Inovio Pharmaceuticals
90 Inovio Pharmaceuticals allegedly made false and misleading statements
90 Inovio Pharmaceuticals stock price fell
85 Faruqi & Faruqi investigating potential claims and reminding investors of class action deadline Inovio Pharmaceuticals
Entities Involved
stock
Inovio Pharmaceuticals
Inovio Pharmaceuticals is facing a federal securities class action lawsuit due to allegedly making false and misleading statements regarding its CELLECTRA device manufacturing, BLA submission timeline for INO-3107, and eligibility for FDA accelerated approval. Its stock price fell significantly after the United States===Food and Drug Administration's announcement.
Importance 100 Sentiment -70
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration accepted Inovio Pharmaceuticals' Biologics License Application for INO-3107 on a standard review timeline, stating that Inovio Pharmaceuticals did not submit adequate information to justify eligibility for accelerated approval.
Importance 80 Sentiment 0
priv
The Schall Law Firm
The Schall Law Firm is representing investors in a class action lawsuit against Inovio Pharmaceuticals, seeking to recover losses for shareholders who purchased the company's securities during the specified Class Period.
Importance 80 Sentiment 50
priv
Faruqi & Faruqi
Faruqi & Faruqi, a national securities law firm, is investigating potential claims against Inovio Pharmaceuticals and is reminding investors of the deadline to seek the role of lead plaintiff in a federal securities class action.
Importance 70 Sentiment 10
per
James Wilson (lawyer)
James Wilson, a partner at Faruqi & Faruqi, is encouraging investors who suffered losses in Inovio Pharmaceuticals to contact him directly to discuss their legal options.
Importance 60 Sentiment 10
priv
The Gross Law Firm
The Gross Law Firm is initiating and representing shareholders in a class action lawsuit against Inovio Pharmaceuticals. This action is part of their business model to protect investors and seek recovery for losses due to alleged corporate misconduct.
Importance 60 Sentiment 20
priv
Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP is representing investors in a securities fraud class action lawsuit against Inovio Pharmaceuticals, seeking to recover losses for shareholders.
Importance 40 Sentiment 50
+ 3 more entities View on Dashboard
Relationships
Faruqi & Faruqi related ↔ Inovio Pharmaceuticals
James Wilson (lawyer) related ↔ Faruqi & Faruqi
United States===Food and Drug Administration related ↔ Inovio Pharmaceuticals
Faruqi & Faruqi related ↔ United States===Food and Drug Administration
Inovio Pharmaceuticals related ↔ United States===Food and Drug Administration
Inovio Pharmaceuticals related ↔ The Schall Law Firm
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.